No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CRDF241220C3000
- 0.91
- +0.43+89.58%
15min DelayClose Dec 13 15:59 ET
0.91High0.70Low
0.70Open0.48Pre Close300 Volume308 Open Interest3.00Strike Price25.20KTurnover0.00%IV-0.26%PremiumDec 20, 2024Expiry Date0.92Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.31Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Cardiff Oncology Is Maintained at Overweight by Piper Sandler
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Director Gary Pace Buys $940,199 in Stock
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study